3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Sell
38
TRIB Quote, Financials, Valuation and Earnings
Last price:
$0.74
Seasonality move
:
5.2%
Day range:
$0.73 - $0.80
52-week range:
$0.48 - $3.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.14x
P/B ratio:
--
Volume:
14.9K
Avg. volume:
55.4K
1-year change:
-54.32%
Market cap:
$14.5M
Revenue:
$56.8M
EPS (TTM):
-$2.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$16M | -$0.28 | 8.81% | -25.13% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
AKTX
Akari Therapeutics PLC
|
-- | -- | -- | -- | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
DBVT
DBV Technologies SA
|
$501.4K | -$0.24 | -- | -87.95% | $15.52 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$0.75 | -- | $14.5M | -- | $0.00 | 0% | 0.14x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.29 | $1.71 | $75.3M | -- | $0.00 | 0% | 0.42x |
|
AKTX
Akari Therapeutics PLC
|
$1.26 | -- | $36.4M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.41 | $17.94 | $3.6M | -- | $0.00 | 0% | 1.47x |
|
DBVT
DBV Technologies SA
|
$9.83 | $15.52 | $268.9M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.04 | $104.00 | $254.4K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
147.47% | -1.250 | 785.94% | 0.87x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 3.631 | 36.44% | 2.60x |
|
AKTX
Akari Therapeutics PLC
|
-- | -2.630 | -- | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
-- | -3.919 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -0.390 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
AKTX
Akari Therapeutics PLC
|
-- | -$1.9M | -- | -- | -- | -$1.5M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$26.6M | -- | -- | -- | -$19.7M |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
Trinity Biotech PLC vs. Competitors
-
Which has Higher Returns TRIB or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -2303.38%. Trinity Biotech PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About TRIB or ADAP?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1889.92%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 483.13%. Given that Trinity Biotech PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Trinity Biotech PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is TRIB or ADAP More Risky?
Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.
-
Which is a Better Dividend Stock TRIB or ADAP?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or ADAP?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Trinity Biotech PLC's net income of -$4.8M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.14x versus 0.42x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.14x -- $15.2M -$4.8M ADAPAdaptimmune Therapeutics PLC0.42x -- $3.2M -$74.2M
-
Which has Higher Returns TRIB or AKTX?
Akari Therapeutics PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M AKTXAkari Therapeutics PLC-- -$0.24 -- -
What do Analysts Say About TRIB or AKTX?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1889.92%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 6248.7%. Given that Akari Therapeutics PLC has higher upside potential than Trinity Biotech PLC, analysts believe Akari Therapeutics PLC is more attractive than Trinity Biotech PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 AKTXAkari Therapeutics PLC0 0 0 -
Is TRIB or AKTX More Risky?
Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.306%.
-
Which is a Better Dividend Stock TRIB or AKTX?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or AKTX?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.14x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.14x -- $15.2M -$4.8M AKTXAkari Therapeutics PLC-- -- -- -$2.9M
-
Which has Higher Returns TRIB or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About TRIB or BDRX?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1889.92%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1172.62%. Given that Trinity Biotech PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Trinity Biotech PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is TRIB or BDRX More Risky?
Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock TRIB or BDRX?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or BDRX?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.14x versus 1.47x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.14x -- $15.2M -$4.8M BDRXBiodexa Pharmaceuticals PLC1.47x -- -- --
-
Which has Higher Returns TRIB or DBVT?
DBV Technologies SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M DBVTDBV Technologies SA-- -$1.30 -- -
What do Analysts Say About TRIB or DBVT?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1889.92%. On the other hand DBV Technologies SA has an analysts' consensus of $15.52 which suggests that it could grow by 57.86%. Given that Trinity Biotech PLC has higher upside potential than DBV Technologies SA, analysts believe Trinity Biotech PLC is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 DBVTDBV Technologies SA0 0 0 -
Is TRIB or DBVT More Risky?
Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.
-
Which is a Better Dividend Stock TRIB or DBVT?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or DBVT?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than DBV Technologies SA quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.14x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.14x -- $15.2M -$4.8M DBVTDBV Technologies SA-- -- -- -$27.1M
-
Which has Higher Returns TRIB or NCNA?
NuCana PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About TRIB or NCNA?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1889.92%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 247519.05%. Given that NuCana PLC has higher upside potential than Trinity Biotech PLC, analysts believe NuCana PLC is more attractive than Trinity Biotech PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 NCNANuCana PLC0 1 0 -
Is TRIB or NCNA More Risky?
Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.
-
Which is a Better Dividend Stock TRIB or NCNA?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or NCNA?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than NuCana PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is lower than NuCana PLC's net income of -$836.1K. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.14x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.14x -- $15.2M -$4.8M NCNANuCana PLC-- -- -- -$836.1K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Butterfly Network the Best Small-Cap Stock?
Brought to public trading by an SPAC merger in early…
Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
